We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+6.67%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$11.4B
AUM Growth
+$618M
(+5.7%)
Cap. Flow
+$92.8M
Cap. Flow
% of AUM
0.81%
Top 10 Holdings %
Top 10 Hldgs %
22.42%
Holding
322
New
56
Increased
78
Reduced
105
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$128M |
| 2 |
Uber
UBER
|
+$73.3M |
| 3 |
Labcorp
LH
|
+$62.1M |
| 4 |
Baxter International
BAX
|
+$54.5M |
| 5 |
Analog Devices
ADI
|
+$50.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$61.6M |
| 2 |
AABA
Altaba Inc
AABA
|
+$57.7M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$54.4M |
| 4 |
Agilent Technologies
A
|
+$50M |
| 5 |
HCA Healthcare
HCA
|
+$49.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.69% |
| 2 | Financials | 22.5% |
| 3 | Healthcare | 18.14% |
| 4 | Communication Services | 8.23% |
| 5 | Consumer Discretionary | 6.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Ascendis Pharma A/S
ASND
$16.6B
| $2.88M | 0.03% |
+25,000
| New | +$2.99M |
|
227
KVH Industries
KVHI
$180M
| $2.76M | 0.02% |
253,695
| – | – |
|
|
ARQL
228
DELISTED
Arqule Inc
ARQL
| $2.75M | 0.02% |
+250,000
| New | +$1.74M |
|
|
MRTX
229
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.58M | 0.02% |
+25,000
| New | +$1.95M |
|
230
Replimune Group
REPL
$489M
| $2.57M | 0.02% |
175,000
| – | – |
|
231
Crinetics Pharmaceuticals
CRNX
$8.88B
| $2.5M | 0.02% |
+100,000
| New | +$2.48M |
|
232
Supernus Pharmaceuticals
SUPN
$2.78B
| $2.48M | 0.02% |
75,000
| – | – |
|
233
Verisk Analytics
VRSK
$27.9B
| $2.21M | 0.02% |
+15,124
| New | +$2.13M |
|
234
HDFC Bank
HDB
$121B
| $2.17M | 0.02% |
66,716
-6,000
| -8% | -$181K |
|
|
ORTX
235
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $2.1M | 0.02% |
+15,000
| New | +$2.63M |
|
236
eGain
EGAN
$188M
| $2.02M | 0.02% |
248,428
-76,300
| -23% | -$690K |
|
237
Q32 Bio
QTTB
$469M
| $1.96M | 0.02% |
5,556
| – | – |
|
|
BCYC
238
Bicycle Therapeutics
BCYC
$276M
| $1.31M | 0.01% |
+130,000
| New | +$1.57M |
|
|
KZR
239
DELISTED
Kezar Life Sciences
KZR
| $1.16M | 0.01% |
15,000
+5,000
| +50% | +$778K |
|
240
NetEase
NTES
$81.8B
| $935K | 0.01% |
18,275
+3,035
| +20% | +$161K |
|
|
JOBS
241
DELISTED
51job Inc
JOBS
| $893K | 0.01% |
11,829
+2,979
| +34% | +$238K |
|
|
IMMP
242
Immutep
IMMP
$56.4M
| $835K | 0.01% |
459,260
-40,740
| -8% | -$77.9K |
|
|
VNET
243
VNET Group
VNET
$1.9B
| $732K | 0.01% |
93,936
-21,738
| -19% | -$166K |
|
244
Solana Company
HSDT
$96.3M
| – | – |
0
| – | – |
|
|
VRNA
245
DELISTED
Verona Pharma
VRNA
| $510K | ﹤0.01% |
100,000
| – | – |
|
246
Summit Therapeutics
SMMT
$10.2B
| $436K | ﹤0.01% |
344,681
-5,319
| -2% | -$8.9K |
|
247
Mercado Libre
MELI
$94.1B
| $403K | ﹤0.01% |
+658
| New | +$366K |
|
|
RLM
248
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
| $351K | ﹤0.01% |
+124,900
| New | +$412K |
|
|
NBIS
249
Nebius Group N.V.
NBIS
$43.9B
| $340K | ﹤0.01% |
8,953
-5,063
| -36% | -$188K |
|
250
Esquire Financial Holdings
ESQ
$1.06B
| $322K | ﹤0.01% |
12,789
-4,849
| -27% | -$114K |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2019 Portfolio in Review
As of Q2 2019, Polar Capital held 322 positions worth $11.4B, up 5.7% from $10.8B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital's Q2 2019 filing shows 56 new, 78 increased, 105 reduced and 40 closed positions. Its largest new stake was Qualcomm: 1,750,293 shares worth $133M. The largest sale was Abbott, an estimated $61.6M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 27% a quarter earlier, followed by Financials and Healthcare.
- Polar Capital's largest Q2 2019 buy was Qualcomm: 1,750,293 shares worth $133M.
- Polar Capital added most to Baxter International in Q2 2019, an estimated $54.5M increase.
- Polar Capital's biggest Q2 2019 reduction was Abbott, cutting an estimated $61.6M.
- Polar Capital fully exited Altaba Inc in Q2 2019, selling an estimated $57.7M.
- Polar Capital's ten largest holdings make up 22% of its $11.4B portfolio in Q2 2019.
- Polar Capital opened 56 new positions and closed 40 in Q2 2019.
- Polar Capital's portfolio value rose 5.7% quarter-over-quarter to $11.4B.
Based on Polar Capital's 13F filing for Q2 2019, filed 14 Aug 2019.